School of Medicine


Showing 4,461-4,470 of 4,713 Results

  • Irving Weissman

    Irving Weissman

    Virginia & D.K. Ludwig Professor of Clinical Investigation in Cancer Research, Professor of Pathology, and of Developmental Biology

    Current Research and Scholarly InterestsStem cell and cancer stem cell biology; development of T and B lymphocytes; cell-surface receptors for oncornaviruses in leukemia. Hematopoietic stem cells; Lymphocyte homing, lymphoma invasiveness and metastasis; order of events from hematopoietic stem cells [HSC] to AML leukemia stem cells and blood diseases, and parallels in other tissues; discovery of tumor and pathogenic cell 'don't eat me' and 'eat me' signals, and translation into therapeutics.

  • Chad S. Weldy, M.D., Ph.D.

    Chad S. Weldy, M.D., Ph.D.

    Instructor, Medicine - Cardiovascular Medicine

    Current Research and Scholarly InterestsAs a physician-scientist in the lab of Dr. Quertermous I work to understand the genetic basis of cardiovascular disease and the transcriptional and epigenomic mechanisms of atherosclerosis. My work is focused across four main areas of cardiovascular genetics and mechanisms of coronary artery disease and smooth muscle biology:
    1.Vascular smooth muscle specific ADAR1 mediated RNA editing of double stranded RNA and activation of the double stranded RNA receptor MDA5
    2.Defining on single cell resolution the cellular and epigenomic features of human vascular disease across vascular beds of differing embryonic origin
    3.CRISPRi screening with targeted perturb seq (TAPseq) to identify novel CAD genes in human coronary artery smooth muscle cells
    4.Investigation of the epigenetic and molecular basis of coronary artery disease and smooth muscle cell transition in mice with conditional smooth muscle genetic deletion of CAD genes Pdgfd and Sox9

    My work with Dr. Quertermous is focused on discovery of causal mechanisms of disease through leveraging human genetics with sophisticated molecular biology, single cell sequencing technologies, and mouse models of disease. This work attempts to apply multiple scientific research arms to ultimately lead to novel understandings of vascular disease and discover important new therapeutic approaches for drug discovery.

    Grant funding received for this work:

    Mentored Clinical Scientist Research Career Development Award (K08)(NIH/NHLBI, 1 K08 HL167699-01), Submitted June, 2022. PI: Weldy, Chad
    •Title of proposal: “ADAR Mediated RNA editing is a causal mechanism in coronary artery disease”.
    •Pending 08/01/2023 Start date
    •$850,000 over 5 years

    Career Development Award, American Heart Association (AHA CDA)(23CDA1042900), July, 2023 – June, 2026. PI: Weldy, Chad
    •Title of proposal: “Linking RNA editing to coronary artery calcification and disease”
    •Activation on 07/01/2023
    •$231,000 over three years

    NIH Loan Repayment Program (LRP) Award (NIH/NHLBI) Renewal Award, July, 2023. PI: Weldy, Chad
    •Title of proposal: “RNA editing is a causal mechanism of coronary artery disease”

    Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32) (NIH/NHLBI, 1 F32 HL160067-01), July, 2021. PI: Weldy, Chad
    • Titled, “A transcriptional network which governs smooth muscle transition is mediated by causal coronary artery disease gene PDGFD”
    •*Received perfect score with impact score 10, 1st percentile

    NIH Loan Repayment Program (LRP) Award (NIH/NHLBI), July, 2021. PI: Weldy, Chad
    •Title of proposal: "Single cell transcriptomic and epigenomic features of human atherosclerosis".
    •This will award up to $100,000 towards student loans over the next 24 months with opportunity for renewal after 24 months.

  • Andy Wen

    Andy Wen

    Clinical Associate Professor, Pediatrics - Critical Care

    BioDr. Andy Y. Wen joined the Division of Pediatric Critical Care Medicine at Stanford University School of Medicine as Clinical Associate Professor of Pediatrics in 2019. He received his B.A. degree in Molecular Biology & Biochemistry at Rutgers University, and his medical degree from Rutgers Robert Wood Johnson Medical School. He completed a Pediatrics Residency Training Program at the State University of New York Downstate Medical Center and a Pediatric Critical Care Medicine Fellowship Training Program at the University of California Los Angeles.

    After briefly working for Kaiser Permanente Southern California Permanente Medical Group, Dr. Wen joined the Division of Pediatric Critical Care at NYU School of Medicine. He assumed the role of Bellevue Hospital PICU medical director and helped to expand Bellevue's Pediatric Trauma Program and Pediatric Critical Care Transport Services for the New York City (NYC) public hospital system, NYC Health & Hospitals. During the 2014 to 2016 Ebola outbreak in West Africa, Dr. Wen was a member of the Special Pathogens Program at Bellevue Hospital, which was one of only four institutions in the US to treat a patient with Ebola and helped established the National Ebola Training and Education Center (NETEC).

    While at UCLA, Dr. Wen received a T32 Training Grant to perform research investigating the role of transcription factor CREB in innate immune function using a murine model for AML. At NYU, his research projects included analyzing transfusion practices in the PICU, quality improvement projects targeting patients at high risk for unplanned extubation, and exploring the utility of NIRS as an early predictor of seizure activity. Dr. Wen is a member of Pediatric Acute Lung Injury & Sepsis Investigators (PALISI) and has been involved in multi-center studies looking at critical care patients with Bronchiolitis and COVID-19. Dr. Wen is the USA Editor for Journal of Pediatric Intensive Care and has reviewed abstracts for PAS, SCCM, and AMIA. His educational efforts have included teaching Pediatric Fundamental Critical Care Support (PFCCS) courses, helping develop a Pediatric Residency Simulation course curriculum, and helping develop a Point-of-Care Ultrasound course for critical care advanced practice providers.

    At Stanford University School of Medicine, Dr. Wen is in charge of Regional Pediatric Critical Care Outreach with a goal to promote medical education and expand the Stanford Children’s Health network to improve access for sick children in need of high quality care. Dr. Wen provides clinical services at both John Muir Medical Center and Lucile Packard Children’s Hospital.

  • Paul Wender

    Paul Wender

    Francis W. Bergstrom Professor and Professor, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsMolecular imaging, therapeutics, drug delivery, drug mode of action, synthesis

  • Kirsti Weng Elder MD/MPH

    Kirsti Weng Elder MD/MPH

    Clinical Associate Professor, Medicine - Primary Care and Population Health

    BioDr. Weng is the Section Chief of General Primary Care. She has over 25 years of experience caring for patients in primary care, urgent care and in the hospital. She is also a teacher of students and residents. As a leader in primary care re-design, she is passionate about practicing patient-centered medicine. She is a an advocate of Mindfulness Self-compassion to develop equanimity. She practices with an emphasis on musculoskeletal care as she feels fitness is the foundation of wellness. She is a leader in organizational change and physician management. She supports community health and care for the underserved. Outside of work she enjoys biking, reading and spending time with her 8 children.

  • Wen-Kai Weng, MD, PhD

    Wen-Kai Weng, MD, PhD

    Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology

    Current Research and Scholarly InterestsMy research interest is on immunotherapy (including allogeneic transplant) of cancer. I have studies the mechanism of monoclonal antibody therapy in lymphoma patients and am currently working on designing new strategy to enhance the clinical efficacy of antibody therapy by infusing expanded NK cells. I am also interested in using tumor vaccine along with hematopoietic cell transplant.